USANA Projects FY2026 Net Sales of $720 to $765 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
The company's initial fiscal 2026 net sales outlook reflects: Net sales from USANA, our core nutritional business, of $720 to $765 million (compared to preliminary net sales for fiscal 2025 of approximately $777 million); Net sales from Hiya of $140 to $155 million (compared to preliminary net sales for fiscal 2025 of approximately $132 million); Net sales from Rise Wellness of $65 to $80 million (compared to preliminary net sales for fiscal 2025 of approximately $16 million); and Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025 (impacts the core nutritional business). Rise Wellness (comprising two brands - Rise Bar and Protein Pop) experienced meaningful year-over-year net sales growth in 2025 and expects accelerated growth during fiscal 2026. Consequently, operating margins in this business are expected to be at breakeven in fiscal 2026 as it invests in strategic activities to drive future growth. Additionally, the company is making meaningful investments at both Rise Wellness and Hiya in inventory, capital expenditures and other working capital needs to support the early growth stages of these businesses. FY26 revenue consensus one analyst estimate of $905.37M.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like USNA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on USNA
Wall Street analysts forecast USNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for USNA is 39.00 USD with a low forecast of 39.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 21.370
Low
39.00
Averages
39.00
High
39.00
Current: 21.370
Low
39.00
Averages
39.00
High
39.00
About USNA
USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Strategic Partnership: Doseology has formed a strategic partnership with McKinney Regulatory Science Advisors to enhance its regulatory compliance capabilities, ensuring product development meets stringent FDA requirements, thereby accelerating market entry and strengthening competitiveness.
- Market Outlook: The global pouch market is projected to exceed $69.46 billion by 2032, and through its collaboration with McKinney, Doseology aims to secure a leading position in this rapidly growing market, driving the commercialization of its innovative oral products.
- Compliance Advantage: McKinney will provide Doseology with comprehensive regulatory guidance, including PMTA preparation and post-market compliance, ensuring its products gain approval in a complex regulatory environment, thus reducing market access risks.
- Science-Driven Approach: Doseology is committed to a science and innovation-driven strategy, ensuring its products not only meet consumer demands but also gain regulatory recognition, thereby establishing a sustainable business model in a competitive market.
Continue Reading
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance
- Market Potential: The global consumer healthcare market is projected to reach $362.17 billion by 2026, and Doseology is enhancing its regulatory compliance capabilities through a partnership with McKinney Regulatory Science Advisors, thereby strengthening its competitive position in this landscape.
- Strategic Collaboration: The partnership with McKinney will encompass formulation strategy, data generation, and PMTA preparation, ensuring that Doseology's product development is not only innovative but also aligned with regulatory expectations, laying the groundwork for entry into a global pouch market expected to exceed $69.46 billion.
- Clear Regulatory Pathway: McKinney's expert guidance will assist Doseology in expediting market access under FDA requirements while strengthening intellectual property protection through aligned formulation and testing strategies, ensuring its products stand out in a competitive market.
- Leadership Team Enhancement: Doseology has appointed Patrick Sills, a former executive from Swedish Match and Philip Morris International, as its commercial leader, combining a robust regulatory strategy with secured manufacturing infrastructure to propel the company towards market entry, showcasing strong growth potential.
Continue Reading